



THE SENATE

FOREIGN AFFAIRS, DEFENCE AND TRADE REFERENCES COMMITTEE

Use of the Quinoline anti-malarial drugs Mefloquine and Tafenoquine in the Australian Defence Force

**PUBLIC HEARING
Thursday 8 November 2018**

**Committee Room 2S1
Parliament House, Canberra**

Time	Witness
9.00 am	Roche Products Pty Ltd (via teleconference) (Submission 12) Mr Svend Petersen, Managing Director Dr Peter Stewart, Medical Director Ms Natalie Touzell, Director, Regulatory Affairs Australia-New Zealand
9.40 am	GlaxoSmithKline Australia Pty Ltd (Submission 8) Mr David Herd, Director, Market Access and Communications and Government Affairs Dr Alison Webster, Head, Global Health Clinical R&D (Global representative, UK) Dr Carolyn Tucek-Szabo, Head, Regulatory Affairs, Australasia
10.20 am	<i>Break</i>
10.30 am	60 Degrees Pharmaceuticals LLC (Submission 9) Dr Geoff Dow Bioclect Pty Ltd (Submission 11) Mr Karl Herz, Managing Director
11.30 am	<i>Adjournment</i>